Cited by 163Virus-based gene therapy researchRNA Interference and Gene DeliveryBarrier Structure and Function Studies

The DOI matches its Crossref record; 62 of the 62 references it cites were found in a registry or an index.

Liver-specific microRNA-122 target sequences incorporated in AAV vectors efficiently inhibits transgene expression in the liver

Open access

Qiao, C, Yuan, Z, Li, J, He, B, Zheng, H, Mayer, C, Li, J, Xiao, X·2011·Gene Therapy

DOI 10.1038/gt.2010.157PMC PMC3686499

Open this paper in CoChat — free account

Abstract

Vectors based on adeno-associated virus (AAV) are effective in gene delivery in vivo. Tissue-specific gene expression is often needed to minimize ectopic expression in unintended cells and undesirable consequences. Here, we investigated whether incorporation of target sequences of tissue-specific microRNA (miRNA) into AAV vectors could inhibit ectopic expression in tissues such as the liver and hematopoietic cells. First we inserted liver-specific miR-122 target sequences (miR-122T) into the 3'-untranslated region (UTR) of a number of AAV vectors. After intravenous delivery in mice, we found that five copies of the 20mer miR-122T reduced liver expression of luciferase by 50-fold and β-galactosidase (LacZ) by 70-fold. Five copies of miR-122T also reduced mRNA levels of a secretable protein (myostatin propeptide) from the AAV vector plasmid by 23-fold in the liver. However, gene expression in other tissues, including the heart was not inhibited. Similarly, we inserted four copies of miR-142-3pT or miR-142-5pT, both hematopoietic lineage-specific, into the 3'-UTR of the AAV-luciferase vector. We wished to see whether they could prolong transgene expression by inhibiting expression in antigen-presenting cells. However, in vivo luciferase gene expression in major tissues declined with time, regardless of the miR-142 target sequences used. Quantitative analysis of the vector DNA in various tissues revealed that the decline of transgene expression in vivo was mainly because of promoter shut-off other than loss of AAV-transduced cells by immune destruction. Moreover, transgene expression was not detected in circulating mononuclear cells after delivering AAV9 vector with or without miR142T. These results demonstrate that liver-specific miR-122 target sequence in AAV vectors was highly efficient in reducing liver expression, whereas hematopoietic miR-142 target sequences were ineffective in preventing decline of AAV vector gene expression in nonhematopoietic tissues resulted from promoter shut-off.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1038/gt.2010.157

Cites

62 of 62 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Identification of Novel Genes Coding for Small Expressed RNAs
Lagos-Quintana, M., Rauhut, R., Lendeckel, W., & Tuschl, T. (2001) · Science · doi:10.1126/science.1064921 · Cited by 4,956
Mammalian microRNAs predominantly act to decrease target mRNA levels
Guo, H., Ingolia, N. T., Weissman, J. S., & Bartel, D. P. (2010) · Nature · doi:10.1038/nature09267 · Cited by 3,886
Successful transduction of liver in hemophilia by AAV-Factor IX and limitations imposed by the host immune response
Manno, C. S., Pierce, G. F., Arruda, V. R., Glader, B., Ragni, M., Rasko, J. J. E., Ozelo, M. C., Hoots, K., Blatt, P., Konkle, B., et al. (2006) · Nature Medicine · doi:10.1038/nm1358 · Cited by 2,163
Safety and Efficacy of Gene Transfer for Leber's Congenital Amaurosis
Maguire, A. M., Simonelli, F., Pierce, E. A., Pugh, E. N., Mingozzi, F., Bennicelli, J., Banfi, S., Marshall, K. A., Testa, F., Surace, E. M., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0802315 · Cited by 2,145
Production of High-Titer Recombinant Adeno-Associated Virus Vectors in the Absence of Helper Adenovirus
Xiao, X., Li, J., & Samulski, R. J. (1998) · Journal of Virology · doi:10.1128/jvi.72.3.2224-2232.1998 · Cited by 1,381
Self-citation
Safety and tolerability of gene therapy with an adeno-associated virus (AAV) borne GAD gene for Parkinson’s disease: an open label, phase I trial
Kaplitt, M. G., Feigin, A., Tang, C., Fitzsimons, H. L., Mattis, P., Lawlor, P. A., Bland, R. J., Young, D., Strybing, K., Eidelberg, D., et al. (2007) · The Lancet · doi:10.1016/s0140-6736(07)60982-9 · Cited by 1,067
Treatment of Leber Congenital Amaurosis Due to RPE65 Mutations by Ocular Subretinal Injection of Adeno-Associated Virus Gene Vector: Short-Term Results of a Phase I Trial
Hauswirth, W. W., Aleman, T. S., Kaushal, S., Cideciyan, A. V., Schwartz, S. B., Wang, L., Conlon, T. J., Boye, S. L., Flotte, T. R., Byrne, B. J., et al. (2008) · Human Gene Therapy · doi:10.1089/hum.2008.107 · Cited by 954
Gene therapy using adeno-associated virus vectors
Daya, S., & Berns, K. I. (2008) · Clinical Microbiology Reviews · doi:10.1128/cmr.00008-08 · Cited by 926
Efficient long-term gene transfer into muscle tissue of immunocompetent mice by adeno-associated virus vector
Xiao, X., Li, J., & Samulski, R. J. (1996) · Journal of Virology · doi:10.1128/jvi.70.11.8098-8108.1996 · Cited by 913
Self-citation
Age-dependent effects of RPE65 gene therapy for Leber's congenital amaurosis: a phase 1 dose-escalation trial
Maguire, A. M., High, K. A., Auricchio, A., Wright, J. F., Pierce, E. A., Testa, F., Mingozzi, F., Bennicelli, J. L., Ying, G.-S., Rossi, S., et al. (2009) · The Lancet · doi:10.1016/s0140-6736(09)61836-5 · Cited by 865

Show all 62 references

Sorted by citations

Adeno-associated virus vector as a platform for gene therapy delivery
Wang, D., Tai, P. W. L., & Gao, G. (2019) · Nature Reviews Drug Discovery · doi:10.1038/s41573-019-0012-9 · Cited by 2,444
AAV-Mediated Gene Therapy for Research and Therapeutic Purposes
Samulski, R. J., & Muzyczka, N. (2014) · Annual Review of Virology · doi:10.1146/annurev-virology-031413-085355 · Cited by 609
CRISPR-Based Therapeutic Genome Editing: Strategies and In Vivo Delivery by AAV Vectors
Wang, D., Zhang, F., & Gao, G. (2020) · Cell · doi:10.1016/j.cell.2020.03.023 · Cited by 539
FGF21 gene therapy as treatment for obesity and insulin resistance
Jiménez, V., Jambrina, C., Casana, E., Sacristan, V., MUÑOZ, S. A., Darriba, S., Rodó, J., Mallol, C., García, M., León, X., et al. (2018) · EMBO Molecular Medicine · doi:10.15252/emmm.201708791 · Cited by 319
Recent Advances in miRNA Delivery Systems
Dasgupta, I., & Chatterjee, A. (2021) · Methods and Protocols · doi:10.3390/mps4010010 · Cited by 322
Adeno-Associated Virus-Based Gene Therapy for CNS Diseases
Hocquemiller, M., Giersch, L., Audrain, M., Parker, S., & Cartier, N. (2016) · Human Gene Therapy · doi:10.1089/hum.2016.087 · Cited by 291
Overcoming innate immune barriers that impede AAV gene therapy vectors
Muhuri, M., Maeda, Y., Ma, H., Ram, S., Fitzgerald, K. A., Tai, P. W. L., & Gao, G. (2021) · Journal of Clinical Investigation · doi:10.1172/jci143780 · Cited by 212
Engineering Liver-detargeted AAV9 Vectors for Cardiac and Musculoskeletal Gene Transfer
Pulicherla, N., Shen, S., Yadav, S. S., Debbink, K. M., Govindasamy, L., Agbandje‐McKenna, M., & Asokan, A. (2011) · Molecular Therapy · doi:10.1038/mt.2011.22 · Cited by 229
Global CNS Transduction of Adult Mice by Intravenously Delivered rAAVrh.8 and rAAVrh.10 and Nonhuman Primates by rAAVrh.10
Yang, B., Li, S., Wang, H., Guo, Y., Gessler, D. J., Cao, C., Su, Q., Kramer, J., Zhong, L., Ahmed, S. S., et al. (2014) · Molecular Therapy · doi:10.1038/mt.2014.68 · Cited by 213
A selective microRNA-based strategy inhibits restenosis while preserving endothelial function
Santulli, G., Wronska, A., Uryu, K., Diacovo, T. G., Gao, M., Marx, S. O., Kitajewski, J., Chilton, J. M., Akat, K. M., Tuschl, T., et al. (2014) · Journal of Clinical Investigation · doi:10.1172/jci76069 · Cited by 179
Controlling AAV Tropism in the Nervous System with Natural and Engineered Capsids
Castle, M. J., Turunen, H. T., Vandenberghe, L. H., & Wolfe, J. H. (2016) · Methods in Molecular Biology · doi:10.1007/978-1-4939-3271-9_10 · Cited by 151
Next-generation AAV vectors—Do not judge a virus (only) by its cover
Domenger, C., & Grimm, D. (2019) · Human Molecular Genetics · doi:10.1093/hmg/ddz148 · Cited by 147
Microneedle-mediated gene delivery for the treatment of ischemic myocardial disease
Shi, H., Xue, T., Yang, Y., Jiang, C., Huang, S., Yang, Q., Lei, D., You, Z., Jin, T., Wu, F., et al. (2020) · Science Advances · doi:10.1126/sciadv.aaz3621 · Cited by 147
Durability of transgene expression after rAAV gene therapy
Muhuri, M., Lévy, D., Schulz, M., McCarty, D. M., & Gao, G. (2022) · Molecular Therapy · doi:10.1016/j.ymthe.2022.03.004 · Cited by 160
Adeno-Associated Virus Vectors as Therapeutic and Investigational Tools in the Cardiovascular System
Zacchigna, S., Zentilin, L., & Giacca, M. (2014) · Circulation Research · doi:10.1161/circresaha.114.302331 · Cited by 144
Adeno-Associated Virus Vectors and Neurological Gene Therapy
Ojala, D. S., Amara, D. P., & Schaffer, D. V. (2014) · The Neuroscientist · doi:10.1177/1073858414521870 · Cited by 143
CRISPR Modeling and Correction of Cardiovascular Disease
Liu, N., & Olson, E. N. (2022) · Circulation Research · doi:10.1161/circresaha.122.320496 · Cited by 120
Adeno‐associated virus (AAV) vectors in gene therapy: immune challenges and strategies to circumvent them
Hareendran, S., Balakrishnan, B., Sen, D., Kumar, S., Srivastava, A., & Jayandharan, G. R. (2013) · Reviews in Medical Virology · doi:10.1002/rmv.1762 · Cited by 113
FGF1 and insulin control lipolysis by convergent pathways
Sancar, G., Liu, S., Gasser, E., Alvarez, J. G. A., Moutos, C. P., Kim, K., van Zutphen, T., Wang, Y., Huddy, T. F., Ross, B., et al. (2022) · Cell Metabolism · doi:10.1016/j.cmet.2021.12.004 · Cited by 107
Emerging Technologies for Delivery of Biotherapeutics and Gene Therapy Across the Blood–Brain Barrier
Stanimirovic, D. B., Sandhu, J. K., & Costain, W. J. (2018) · BioDrugs · doi:10.1007/s40259-018-0309-y · Cited by 109
Enhancing Muscle Membrane Repair by Gene Delivery of MG53 Ameliorates Muscular Dystrophy and Heart Failure in δ-Sarcoglycan-deficient Hamsters
He, B., Tang, R., Weisleder, N. L., Xiao, B., Yuan, Z., Cai, C., Hua Zhu, C., Lin, P., Qiao, C., Li, J., et al. (2012) · Molecular Therapy · doi:10.1038/mt.2012.5 · Cited by 98
Self-citation
Gene Therapy for Glaucoma by Ciliary Body Aquaporin 1 Disruption Using CRISPR-Cas9
Wu, J., Bell, O. H., Copland, D. A., Young, A., Pooley, J. R., Maswood, R. N., Evans, R. S., Khaw, P. T., Ali, R. R., Dick, A. D., et al. (2020) · Molecular Therapy · doi:10.1016/j.ymthe.2019.12.012 · Cited by 100
MicroRNA-regulated viral vectors for gene therapy
Geisler, A., & Fechner, H. (2016) · World Journal of Experimental Medicine · doi:10.5493/wjem.v6.i2.37 · Cited by 100
Rapid and highly efficient inducible cardiac gene knockout in adult mice using AAV-mediated expression of Cre recombinase
Werfel, S., Jungmann, A., Lehmann, L., Ksienzyk, J., Bekeredjian, R., Kaya, Z., Leuchs, B., Nordheim, A., Backs, J., Engelhardt, S. H., et al. (2014) · Cardiovascular Research · doi:10.1093/cvr/cvu174 · Cited by 94
In Vivo Adeno-Associated Viral Vector–Mediated Genetic Engineering of White and Brown Adipose Tissue in Adult Mice
Jiménez, V., MUÑOZ, S. A., Casana, E., Mallol, C., Elias, I., Jambrina, C., Ribera, A., Ferré, T., Franckhauser, S., & Bosch, F. (2013) · Diabetes · doi:10.2337/db13-0311 · Cited by 93
CRISPR genome engineering and viral gene delivery: A case of mutual attraction
Schmidt, F., & Grimm, D. (2015) · Biotechnology Journal · doi:10.1002/biot.201400529 · Cited by 85
AAV Ancestral Reconstruction Library Enables Selection of Broadly Infectious Viral Variants
Santiago-Ortiz, J., Ojala, D. S., Westesson, O., Weinstein, J. R., Wong, S. Y., Steinsapir, A., Kumar, S., Holmes, I., & Schaffer, D. V. (2015) · Gene Therapy · doi:10.1038/gt.2015.74 · Cited by 83
Adeno-associated Virus 9 Mediated FKRP Gene Therapy Restores Functional Glycosylation of α-dystroglycan and Improves Muscle Functions
Xu, L., Lu, P., Wang, C., Keramaris, E., Qiao, C., Xiao, B., Blake, D. J., Xiao, X., & Lu, Q. L. (2013) · Molecular Therapy · doi:10.1038/mt.2013.156 · Cited by 88
Self-citation
Engineered microRNA-based regulatory element permits safe high-dose mini MECP2 gene therapy in Rett mice
Sinnett, S. E., Boyle, E., Lyons, C., & Gray, S. J. (2021) · Brain · doi:10.1093/brain/awab182 · Cited by 81
Adeno-Associated Viruses (AAV) and Host Immunity – A Race Between the Hare and the Hedgehog
Rapti, K., & Grimm, D. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.753467 · Cited by 73
Mir‐142‐3p target sequences reduce transgene‐directed immunogenicity following intramuscular adeno‐associated virus 1 vector‐mediated gene delivery
Majowicz, A., Maczuga, P., Kwikkers, K. L., van der Marel, S., van Logtenstein, R., Petry, H., van Deventer, S. J. H., Konstantinova, P. S., & Ferreira, V. (2013) · The Journal of Gene Medicine · doi:10.1002/jgm.2712 · Cited by 72
Prolonged Gene Expression in Muscle Is Achieved Without Active Immune Tolerance Using MicrorRNA 142.3p-Regulated rAAV Gene Transfer
Boisgerault, F., Gross, D.-A., Ferrand, M., Poupiot, J., Darocha, S., Richard, I., & Galy, A. (2013) · Human Gene Therapy · doi:10.1089/hum.2012.208 · Cited by 63
Systemic injection of AAV9 carrying a periostin promoter targets gene expression to a myofibroblast-like lineage in mouse hearts after reperfused myocardial infarction
Piras, B. A., Tian, Y., Xu, Y., Thomas, N. A., O’Connor, D. M., & French, B. A. (2016) · Gene Therapy · doi:10.1038/gt.2016.20 · Cited by 63
Targeting adipose tissue via systemic gene therapy
O'Neill, S. M., Hinkle, C. C., Chen, S.-J., Sandhu, A. P. S., Hovhannisyan, R. H., Stephan, S., Lagor, W. R., Ahima, R. S., Johnston, J. C., & Reilly, M. P. (2014) · Gene Therapy · doi:10.1038/gt.2014.38 · Cited by 63
Systemic administration of novel engineered AAV capsids facilitates enhanced transgene expression in the macaque CNS
Stanton, A. C., Lagerborg, K. A., Tellez, L., Krunnfusz, A., King, E. M., Ye, S. H., Solomon, I. H., Tabebordbar, M., & Sabeti, P. C. (2022) · Med · doi:10.1016/j.medj.2022.11.002 · Cited by 62
Muscle and Heart Function Restoration in a Limb Girdle Muscular Dystrophy 2I (LGMD2I) Mouse Model by Systemic FKRP Gene Delivery
Qiao, C., Wang, C., Zhao, C., Lu, P., Awano, H., Xiao, B., Li, J., Yuan, Z., Dai, Y., Martin, C. B., et al. (2014) · Molecular Therapy · doi:10.1038/mt.2014.141 · Cited by 60
Self-citation
Gene therapy and neurodevelopmental disorders
Gray, S. J. (2012) · Neuropharmacology · doi:10.1016/j.neuropharm.2012.06.024 · Cited by 61
Epigenetic regulation of miR-200 as the potential strategy for the therapy against triple-negative breast cancer
Ramaiah, M. J., Naushad, S. M., Ponnusamy, L., Arivazhagan, G., Sakthiprasad, V., & Pal‐Bhadra, M. (2017) · Gene · doi:10.1016/j.gene.2017.10.018 · Cited by 59
Intramuscular Injection of AAV8 in Mice and Macaques Is Associated with Substantial Hepatic Targeting and Transgene Expression
Greig, J. A., Peng, H., Ohlstein, J. F., Medina-Jaszek, C. A., Ahonkhai, O., Mentzinger, A., Grant, R. L., Roy, S., Chen, S., Bell, P. L., et al. (2014) · PLoS ONE · doi:10.1371/journal.pone.0112268 · Cited by 55
Circumventing cellular immunity by miR142-mediated regulation sufficiently supports rAAV-delivered OVA expression without activating humoral immunity
Xiao, Y., Muhuri, M., Li, S., Qin, W., Xu, G., Luo, L., Li, J., Letizia, A. J., Wang, S. K., Chan, Y. K., et al. (2019) · JCI Insight · doi:10.1172/jci.insight.99052 · Cited by 53
Self-citation
Spatial transcriptomics for profiling the tropism of viral vectors in tissues
Jang, M. J., Coughlin, G. M., Jackson, C. R., Chen, X., Chuapoco, M. R., Vendemiatti, J., Wang, A. Z., & Gradinaru, V. (2023) · Nature Biotechnology · doi:10.1038/s41587-022-01648-w · Cited by 57
Next-generation AAV vectors for clinical use: an ever-accelerating race
Weinmann, J., & Grimm, D. (2017) · Virus Genes · doi:10.1007/s11262-017-1502-7 · Cited by 54
Optimized circular RNA vaccines for superior cancer immunotherapy
Yu, H., Wen, Y., Yu, W., Lu, L., Yu, Y., Liu, C., Hu, Z., Fang, Z., & Huang, S. (2024) · Theranostics · doi:10.7150/thno.104698 · Cited by 53
Targeting transgene to the heart and liver with AAV 9 by different promoters
Chen, B., He, C., Chen, X., Pan, S., Liu, F., Ma, X., Li, X., Gai, M., Tao, J., Ma, Y., et al. (2015) · Clinical and Experimental Pharmacology and Physiology · doi:10.1111/1440-1681.12453 · Cited by 53
Novel Combinatorial MicroRNA-Binding Sites in AAV Vectors Synergistically Diminish Antigen Presentation and Transgene Immunity for Efficient and Stable Transduction
Muhuri, M., Zhan, W., Maeda, Y., Li, J., Lotun, A., Chen, J., Sylvia, K., Dasgupta, I., Arjomandnejad, M., Nixon, T., et al. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.674242 · Cited by 50
Self-citation
Adipose Tissue: An Emerging Target for Adeno-associated Viral Vectors
Bates, R., Huang, W., & Cao, L. (2020) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2020.09.009 · Cited by 51
Endothelial transcription factor KLF2 negatively regulates liver regeneration via induction of activin A
Manavski, Y., Abel, T., Hu, J., Kleinlützum, D., Buchholz, C. J., Belz, C., Augustin, H. G., Boon, R. A., & Dimmeler, S. (2017) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1613392114 · Cited by 50
Challenges in adeno-associated virus-based treatment of central nervous system diseases through systemic injection
Huang, L., Wan, J., Wu, Y., Tian, Y., Yao, Y., Yao, S., Ji, X., Wang, S., Su, Z., & Xu, H. (2021) · Life Sciences · doi:10.1016/j.lfs.2021.119142 · Cited by 49
Synthetic Biology: Emerging Concepts to Design and Advance Adeno‐Associated Viral Vectors for Gene Therapy
Wagner, H. J., Weber, W., & Fussenegger, M. (2021) · Advanced Science · doi:10.1002/advs.202004018 · Cited by 52
Designing and optimizing AAV-mediated gene therapy for neurodegenerative diseases: from bench to bedside
Xu, L., Yao, S., Ding, Y. E., Xie, M., Feng, D., Sha, P., Tan, L., Bei, F., & Yao, Y. (2024) · Journal of Translational Medicine · doi:10.1186/s12967-024-05661-2 · Cited by 48
Adipose tissue insulin receptor knockdown via a new primate-derived hybrid recombinant AAV serotype
Liu, X., Magee, D., Wang, C., McMurphy, T. B., Slater, A., During, M. J., & Cao, L. (2014) · Molecular Therapy — Methods & Clinical Development · doi:10.1038/mtm.2013.8 · Cited by 46
Gene therapy and editing: Novel potential treatments for neuronal channelopathies
Wykes, R. C., & Lignani, G. (2017) · Neuropharmacology · doi:10.1016/j.neuropharm.2017.05.029 · Cited by 51
Mapping and targeted viral activation of pancreatic nerves in mice reveal their roles in the regulation of glucose metabolism
Jimenez-Gonzalez, M., Li, R., Pomeranz, L., Alvarsson, A., Marongiu, R., Hampton, R. F., Kaplitt, M., Vasavada, R., Schwartz, G., & Stanley, S. (2022) · Nature Biomedical Engineering · doi:10.1038/s41551-022-00909-y · Cited by 35
Targeting Visceral Fat by Intraperitoneal Delivery of Novel AAV Serotype Vector Restricting Off-Target Transduction in Liver
Huang, W., Liu, X., Queen, N. J., & Cao, L. (2017) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2017.06.002 · Cited by 41
MicroRNA silencing and the development of novel therapies for liver disease
Szabó, G., Sarnow, P., & Bala, S. (2012) · Journal of Hepatology · doi:10.1016/j.jhep.2012.01.030 · Cited by 40
Understanding and Tackling Immune Responses to Adeno-Associated Viral Vectors
Verdera, H. C., Unzu, C., Valeri, E., Adriouch, S., González‐Aseguinolaza, G., Mingozzi, F., & Kajaste‐Rudnitski, A. (2023) · Human Gene Therapy · doi:10.1089/hum.2023.119 · Cited by 45
MetALD: Does it require a different therapeutic option?
Marek, G. W., & Malhi, H. (2024) · Hepatology · doi:10.1097/hep.0000000000000935 · Cited by 41
Reducing off-target expression of mRNA therapeutics and vaccines in the liver with microRNA binding sites
Parrett, B. J., Yamaoka, S., & Barry, M. A. (2024) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2024.101402 · Cited by 43
Repeated AAV-mediated gene transfer by serotype switching enables long-lasting therapeutic levels of hUgt1a1 enzyme in a mouse model of crigler–najjar syndrome type I
Bočkor, L., Bortolussi, G., Iaconcig, A., Chiaruttini, G., Tiribelli, C., Giacca, M., Benvenuti, F., Zentilin, L., & Muro, A. F. (2017) · Gene Therapy · doi:10.1038/gt.2017.75 · Cited by 32
Gene Replacement Therapies for Duchenne Muscular Dystrophy Using Adeno-Associated Viral Vectors
Seto, J. T., Ramos, J. N., Muir, L. A., Chamberlain, J. S., & Odom, G. L. (2012) · Current Gene Therapy · doi:10.2174/156652312800840603 · Cited by 37
Preferential Targeting of Disseminated Liver Tumors Using a Recombinant Adeno-Associated Viral Vector
Peruta, M. D., Badar, A., Rosales, C., Chokshi, S., Kia, A., Nathwani, D., Galante, E., Yan, R., Årstad, E., Davidoff, A. M., et al. (2015) · Human Gene Therapy · doi:10.1089/hum.2014.052 · Cited by 35
Application of Mutated miR-206 Target Sites Enables Skeletal Muscle-specific Silencing of Transgene Expression of Cardiotropic AAV9 Vectors
Geisler, A., Schön, C., Größl, T., Pinkert, S., Stein, E. A., Kurreck, J., Vetter, R., & Fechner, H. (2013) · Molecular Therapy · doi:10.1038/mt.2012.276 · Cited by 36
High throughput screening of novel AAV capsids identifies variants for transduction of adult NSCs within the subventricular zone
Kremer, L. P. M., Cerrizuela, S., Dehler, S., Stiehl, T., Weinmann, J., Abendroth, H., Kleber, S., Laure, A., Andari, J. E., Anders, S., et al. (2021) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2021.07.001 · Cited by 34
The parallel universe: microRNAs and their role in chronic hepatitis, liver tissue damage and hepatocarcinogenesis
Haybaeck, J., & Zeller, N. (2011) · Swiss Medical Weekly · doi:10.4414/smw.2011.13287 · Cited by 34
Strategy to enhance transgene expression in proximity of amyloid plaques in a mouse model of Alzheimer's disease
Weber‐Adrian, D., Kofoed, R. H., Chan, J. W. Y., Silburt, J., Noroozian, Z., Kügler, S., Hynynen, K., & Aubert, I. (2019) · Theranostics · doi:10.7150/thno.36718 · Cited by 36
Systemic and Persistent Muscle Gene Expression in Rhesus Monkeys with a Liver De-Targeted Adeno-Associated Virus Vector
Tarantal, A. F., Lee, C. C. I., Martinez, M. L., Asokan, A., & Samulski, R. J. (2017) · Human Gene Therapy · doi:10.1089/hum.2016.130 · Cited by 33
Treatment of multifocal breast cancer by systemic delivery of dual-targeted adeno-associated viral vectors
Trepel, M., Körbelin, J., Spies, E., Heckmann, M. B., Hunger, A., Fehse, B., Katus, H. A., Kleinschmidt, J. A., Müller, O. J., & Michelfelder, S. (2015) · Gene Therapy · doi:10.1038/gt.2015.52 · Cited by 35
Trends and challenges of AAV-delivered gene editing therapeutics for CNS disorders: Implications for neurodegenerative disease
Kantor, B., O’Donovan, B., & Chiba‐Falek, O. (2025) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2025.102635 · Cited by 38
Enhancing the Utility of Adeno-Associated Virus Gene Transfer through Inducible Tissue-Specific Expression
Chen, S., Johnston, J., Sandhu, A., Bish, L. T., Hovhannisyan, R. H., Jno-Charles, O. C., Sweeney, H. L., & Wilson, J. M. (2013) · Human Gene Therapy Methods · doi:10.1089/hgtb.2012.129 · Cited by 31
MicroRNA-Regulated Gene Delivery Systems for Research and Therapeutic Purposes
Dhungel, B. P., Ramlogan‐Steel, C. A., & Steel, J. C. (2018) · Molecules · doi:10.3390/molecules23071500 · Cited by 34
MicroRNA-122–Mediated Liver Detargeting Enhances the Tissue Specificity of Cardiac Genome Editing
Yang, L., Liu, Z., Chen, G., Chen, Z., Guo, C., Ji, X., Cui, Q., Sun, Y., Hu, X., Zheng, Y., et al. (2024) · Circulation · doi:10.1161/circulationaha.123.065438 · Cited by 29
microRNA and Ovarian Cancer
Langhe, R. (2015) · Advances in experimental medicine and biology · doi:10.1007/978-3-319-23730-5_8 · Cited by 29
Exploiting microRNAs for cell engineering and therapy
Bratkovič, T., Glavan, G., Štrukelj, B., Živin, M., & Rogelj, B. (2012) · Biotechnology Advances · doi:10.1016/j.biotechadv.2012.01.006 · Cited by 29
Targeting Adeno-Associated Virus Vectors for Local Delivery to Fractures and Systemic Delivery to the Skeleton
Lee, L. R., Peacock, L., Lisowski, L., Little, D. G., Munns, C. F., & Schindeler, A. (2019) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2019.08.010 · Cited by 28
Development of AAV-Mediated Gene Therapy Approaches to Treat Skeletal Diseases
Lin, C., Greenblatt, M. B., Gao, G., & Shim, J. (2024) · Human Gene Therapy · doi:10.1089/hum.2024.022 · Cited by 25
AAV- based vector improvements unrelated to capsid protein modification
Shitik, E. M., Shalik, I. K., & Yudkin, D. V. (2023) · Frontiers in Medicine · doi:10.3389/fmed.2023.1106085 · Cited by 28
Current prospects and challenges for epilepsy gene therapy
Weinberg, M. S., & McCown, T. J. (2011) · Experimental Neurology · doi:10.1016/j.expneurol.2011.10.003 · Cited by 24
miRNA Pathway Alteration in Response to Non-Coding RNA Delivery in Viral Vector-Based Gene Therapy
Savenkova, D. A., Makarova, A.-L. A., Shalik, I. K., & Yudkin, D. V. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms232314954 · Cited by 24
Genetic Manipulation of Brown Fat Via Oral Administration of an Engineered Recombinant Adeno-associated Viral Serotype Vector
Huang, W., McMurphy, T. B., Liu, X., Wang, C., & Cao, L. (2016) · Molecular Therapy · doi:10.1038/mt.2016.34 · Cited by 23
Amelioration of Muscle and Nerve Pathology in LAMA2 Muscular Dystrophy by AAV9-Mini-Agrin
Qiao, C., Dai, Y., Nikolova, V. D., Jin, Q., Li, J., Xiao, B., Li, J., Moy, S. S., & Xiao, X. (2018) · Molecular Therapy - Methods & Clinical Development · doi:10.1016/j.omtm.2018.01.005 · Cited by 23
Self-citation
Development of hybrid baculovirus vectors for artificial MicroRNA delivery and prolonged gene suppression
Chen, C., Luo, W., Lo, W., Lin, K., Sung, L., Shih, Y.-S., Chang, Y., & Hu, Y. (2011) · Biotechnology and Bioengineering · doi:10.1002/bit.23250 · Cited by 22
Of rAAV and Men: From Genetic Neuromuscular Disorder Efficacy and Toxicity Preclinical Studies to Clinical Trials and Back
Buscara, L., Gross, D., & Danièle, N. (2020) · Journal of Personalized Medicine · doi:10.3390/jpm10040258 · Cited by 22
Molecular Engineering of Virus Tropism
He, B., Wilson, B., Chen, S., Sharma, K., Scappini, E., Cook, M., Petrovich, R. M., & Martin, N. P. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms252011094 · Cited by 22
Self-citation
The role and mechanism of action of microRNA-122 in cancer: Focusing on the liver
Al-Gazally, M. E., Khan, R., Imran, M., Ramírez‐Coronel, A. A., Alshahrani, S. H., Altalbawy, F. M. A., Jalil, A. T., Romero‐Parra, R. M., Zabibah, R. S., Iqbal, M. S., et al. (2023) · International Immunopharmacology · doi:10.1016/j.intimp.2023.110713 · Cited by 22
Therapeutic applications of noncoding RNAs
Latronico, M. V. G., & Condorelli, G. (2015) · Current Opinion in Cardiology · doi:10.1097/hco.0000000000000162 · Cited by 19
Single Tyrosine Mutation in AAV8 and AAV9 Capsids Is Insufficient to Enhance Gene Delivery to Skeletal Muscle and Heart
Qiao, C., Yuan, Z., Li, J., Tang, R., Li, J., & Xiao, X. (2012) · Human Gene Therapy Methods · doi:10.1089/hgtb.2011.229 · Cited by 19
Self-citation
MicroRNA-150-regulated vectors allow lymphocyte-sparing transgene expression in hematopoietic gene therapy
Lachmann, N., Jagielska, J., Heckl, D., Brennig, S., Pfaff, N., Maetzig, T., Modlich, U., Cantz, T., Gentner, B., Schambach, A., et al. (2011) · Gene Therapy · doi:10.1038/gt.2011.148 · Cited by 17
Variability in Cardiac miRNA-122 Level Determines Therapeutic Potential of miRNA-Regulated AAV Vectors
Kraszewska, I., Tomczyk, M., Andrysiak, K., Biniecka, M., Geisler, A., Fechner, H., Zembala, M. O., Stępniewski, J., Dulak, J., & Jaźwa, A. (2020) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2020.05.006 · Cited by 19
A Workflow for In Vivo Evaluation of Candidate Inputs and Outputs for Cell Classifier Gene Circuits
Dastor, M., Schreiber, J., Prochazka, L., Angelici, B., Kleinert, J., Klebba, I., Doshi, J., Shen, L., & Benenson, Y. (2017) · ACS Synthetic Biology · doi:10.1021/acssynbio.7b00303 · Cited by 13
Breaking the sound barrier: Towards next-generation AAV vectors for gene therapy of hearing disorders
Fakhiri, J., Landegger, L. D., & Grimm, D. (2020) · Hearing Research · doi:10.1016/j.heares.2020.108092 · Cited by 15
iPSC-derived neural precursor cells engineering GBA1 recovers acid β-glucosidase deficiency and diminishes α-synuclein and neuropathology
Peng, Y., Liou, B., Lin, Y., Mayhew, C. N., Fleming, S. M., & Sun, Y. (2023) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2023.03.007 · Cited by 14
MicroRNA as biomarkers of mitochondrial toxicity
Baumgart, B. R., Gray, K. L., Woicke, J., Bunch, R. T., Sanderson, T. P., & Vleet, T. R. V. (2015) · Toxicology and Applied Pharmacology · doi:10.1016/j.taap.2015.10.007 · Cited by 14
Exploring the Therapeutic Potential of Gene Therapy in Arrhythmogenic Right Ventricular Cardiomyopathy
Mundisugih, J., Ravindran, D., & Kizana, E. (2024) · Biomedicines · doi:10.3390/biomedicines12061351 · Cited by 13
The use of miR122 and its target sequence in adeno-associated virus-mediated trichosanthin gene therapy
Ran, G., Feng, X.-L., Xie, Y., Zheng, Q., Guo, P., Yang, M., Feng, Y., Ling, C., Zhu, L., & Chen, Z. (2021) · Journal of Chinese Integrative Medicine · doi:10.1016/j.joim.2021.09.004 · Cited by 14
Therapeutic advances in musculoskeletal AAV targeting approaches
Bulaklak, K., & Xiao, X. (2017) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2017.07.001 · Cited by 13
Self-citation
Identification of a robust promoter in mouse and human hepatocytes by in vivo biopanning of a barcoded AAV library
Becker, J., Domenger, C., Choksi, P. K., Krämer, C., Baumgartl, C., Maiakovska, O., Kim, J.-J., Weinmann, J., Huber, G., Schmidt, F., et al. (2025) · Molecular Therapy · doi:10.1016/j.ymthe.2025.04.027 · Cited by 11
Vector Affinity and Receptor Distribution Define Tissue-Specific Targeting in an Engineered AAV Capsid
Martino, R. A., Wang, Q., Xu, H. Y., Hu, G. B., Bell, P. L., Arroyo, E. J., Sims, J. J., & Wilson, J. M. (2023) · Journal of Virology · doi:10.1128/jvi.00174-23 · Cited by 13
Persistence, Localization, and External Control of Transgene Expression After Single Injection of Adeno-Associated Virus into Injured Joints
Lee, H. H., O’Malley, M. J., Friel, N. A., Payne, K. A., Qiao, C., Xiao, X., & Chu, C. R. (2013) · Human Gene Therapy · doi:10.1089/hum.2012.118 · Cited by 11
Self-citation
Targeted gene delivery systems for T-cell engineering
Wang, F., Huang, Y., Li, J., Zhou, W., & Wang, W. (2024) · Cellular Oncology · doi:10.1007/s13402-024-00954-6 · Cited by 11
Self-citation
Novel AAV variants with improved tropism for human Schwann cells
Drouyer, M., Chu, T., Labit, E., Haase, F., Navarro, R. G., Nazareth, D., Rosin, N. L., Merjane, J., Scott, S., Cabanes‐Creus, M., et al. (2024) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2024.101234 · Cited by 10

Authors: Qiao, C., Yuan, Z., Li, J., He, B., Zheng, H., Mayer, C., Li, J., & Xiao, X.
Affiliations: University of North Carolina at Chapel Hill (US)
Corresponding author: Qiao, C
Xiao, X
ORCID: He, B
Venue: Gene Therapy
Publisher: Springer Science and Business Media LLC
Published: 2010-12-09
Volume: 18
Issue: 4
Pages: 403-410
ISSN: 0969-7128 (ISSN-L)
1476-5462
DOI: 10.1038/gt.2010.157
PMC: PMC3686499
OpenAlex: W2086500311
Cited by: 163
References: 62
Citations by year: 2026: 11 · 2025: 15 · 2024: 16 · 2023: 10 · 2022: 7 · 2021: 13 · 2020: 8 · 2019: 9 · 2018: 7 · 2017: 10 · 2016: 6 · 2015: 12 · 2014: 11 · 2013: 11 · 2012: 8
FWCI: 4.86
Type: journal article
Language: en
Open access: green
www.ncbi.nlm.nih.gov
Licence: www.springer.com/tdm (tdm)
www.springer.com/tdm (vor)
Locations: Gene Therapy (publishedVersion)
PubMed (publishedVersion)
Europe PMC (PubMed Central) (acceptedVersion)
PubMed Central (acceptedVersion)
Carolina Digital Repository (University of North Carolina at Chapel Hill) (submittedVersion)
UNC Libraries
Funders: National Institute of Arthritis and Musculoskeletal and Skin Diseases (AR45967, R01AR045967, AR 56394, R01AR056394)
Topics: Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Virus-based gene therapy research
Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA Interference and Gene Delivery
Life Sciences › Neuroscience › Neurology › Barrier Structure and Function Studies
Keywords: adeno-associated virus vectors, miR-122, miR-142, 3' untranslated region, liver-specific gene expression, tissue-specific gene expression, ectopic expression, hematopoietic cells, AAV9, myostatin propeptide, intravenous gene delivery
MeSH terms: Dependovirus, Animals, Antigen-Presenting Cells, beta-Galactosidase, Gene Expression Regulation, Genetic Vectors, Liver, Luciferases, Organ Specificity, Gene Transfer Techniques, Transgenes, MicroRNAs, Mice, Myostatin

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Liver-specific microRNA-122 target sequences incorporated in AAV vectors efficiently inhibits transgene expression in the liver

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks